Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02284048

Enrollment

140

Registered

2014-11-05

Start date

2014-11-30

Completion date

2017-11-30

Last updated

2014-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microvascular Angina

Keywords

Ticagrelor, Coronary Flow Reserve

Brief summary

This study is undertaken to determine if ticagrelor augments adenosine-induced coronary flow reserve (CFR), ameliorates clinical symptomatology and exercise tolerance in patients with MVA

Detailed description

Considering the reduced CFR and increased platelet aggregability in patients with MVA, together with the augmented effect on adenosine-mediated coronary blood flow and potent antiplatelet effect of ticagrelor, we speculate that ticagrelor can promisingly ameliorate the coronary microvascular function in patients with MVA.

Interventions

DRUGticagrelor

compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

For inclusion in the study subjects should fulfill the following criteria: 1. Provision of informed consent prior to any study specific procedures 2. Female or male aged 18-80 years 3. A diagnosis of stable primary MVA based on the presence of * a history of typical effort angina, * exercise-induced ST-segment depression\>1 mm, * normal or near-normal (coronary artery stenosis\<50%) coronary angiography, * absence vasospastic angina * a coronary flow reserve (CFR) \<2.5 in the left anterior descending coronary artery as assessed by coronary blood flow (CBF) response to adenosine at transthoracic Doppler echocardiography * suboptimal control of symptoms on conventional anti-ischemic therapy, as indicated by the occurrence of \>1 episode per week of angina

Exclusion criteria

ubjects should not enter the study if any of the following

Design outcomes

Primary

Measure	Time frame
adenosine-induced coronary flow reserve (CFR)	2 months

Contacts

Primary ContactDaoquan Peng, MD, PhD

pengdq@hotmail.com86-731-85295806

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026